Bifunctional Pyrimidine Compounds for Selective CDK2 Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CDK2 inhibitors face limitations in efficacy due to resistance mechanisms, particularly through CDK2-mediated pathways, and there is a need for alternative approaches to target CDK2 activity in various cancers and other conditions.
Innovation Solution
Development of bifunctional compounds that recruit CDK2 to a ubiquitin ligase, promoting its degradation via the ubiquitin proteasome pathway, thereby inhibiting CDK2 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CDK4/6 inhibitors are used to treat cancer, then tumor growth is inhibited, but resistance develops over time due to CDK2 activation
Solution Approach 1:
The patent separates the inhibition strategy into two distinct mechanisms: CDK4/6 inhibition (first-generation approach) and CDK2 degradation (second-generation approach). By using bifunctional compounds that can target CDK2 for proteasomal degradation, the therapy addresses the resistance mechanism separately rather than relying solely on continuous CDK4/6 inhibition, thereby extending the duration of response.
Solution Approach 2:
The patent introduces an intermediary mechanism - the ubiquitin-proteasome pathway - to eliminate CDK2 protein. Instead of directly inhibiting CDK2 activity, the bifunctional compounds mediate CDK2 degradation through E3 ligase recruitment, providing a novel approach to overcome resistance while maintaining therapeutic efficacy.
2Reliability
If CDK2 activity is inhibited to overcome resistance, then therapeutic efficacy is improved, but new resistance mechanisms may emerge
Solution Approach 1:
The patent changes the fundamental parameter of CDK2 targeting from activity inhibition to protein degradation. By altering the mechanism of action from blocking kinase activity to eliminating the protein via ubiquitin-proteasome pathway, the therapy achieves superior efficacy against resistant cancers while the bifunctional nature allows adaptation to different resistance profiles.
Solution Approach 2:
The bifunctional compounds described in the patent possess multiple capabilities: they can inhibit CDK2 activity directly and simultaneously recruit CDK2 for proteasomal degradation. This multi-functionality enhances adaptability to various resistance mechanisms, as the compounds can engage different pathways (kinase inhibition or protein degradation) depending on the cancer's resistance profile.
3Reliability
If selective CDK2 degradation is achieved, then specificity and efficacy are improved, but compound complexity increases
Solution Approach 1:
The patent merges two distinct functional motifs into single bifunctional compounds: a CDK2 inhibitory moiety and an E3 ligase recruitment element. This combination achieves selective CDK2 degradation through a unified molecular structure, improving specificity while the modular design approach helps manage the inherent complexity by combining well-established pharmacological fragments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds selectively degrade CDK2, offering therapeutic potential for cancers resistant to CDK4/6 inhibitors and addressing conditions like noise-, cisplatin-, or age-related hearing loss.
Implementation Method 1
bifunctional compounds that recruit CDK2 to a ubiquitin ligase, promoting its degradation via the ubiquitin proteasome pathway
Data Source
AI summary
The present disclosure provides certain bifunctional compounds containing substituted pyrimidine derivatives substituted at the 4-position with a cyclic group that cause degradation of Cyclin-dependent kinase 2 (CDK2) via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by CDK2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.